Merger closed, proposed name announced, AGM in 21 days... What happens before and at the AGM before the vote?
Nothing?
1) The last person last visit for the diagnostic clinical trial was 11 days ago with top-line results expected in Q3. Do we get the top-line results? A licensing deal?
2) Approximately two months ago with three trial runs completed the 50L PGX scale-up was said "almost completed". Do we get an announcement that it has been completed and an update on the 100L scale-up with NATEX? The 50L scale-up was previously expected to provide materials for potential partners. Do we get a PGX deal? In its November news release CZO also said that it had designed an animal trial protocol for the immune booster.
3) Approximately one month ago a full report from the avenanthramide clinical trial was expected "shortly": No significant adverse reactions have been observed during this SAD phase. Based on full report to be completed shortly, members of the Data Safety Monitoring Board will decide on conducting the next step of the Phase 1 study consisting of three additional groups of 8 subjects per group where each subject will receive multiple ascending dose (MAD). The Company expects to initiate the MAD arm during the summer 2024." news release
We have never seen any preclinical or clinical data for this pill previously or much of an explaination concerning what exactly the formulation is that may make it special compared to previous avenanthramide clinical trials. CZO also previously announced that it hd been experimenting with newer generation PGX carriers and avenanthramide.
4) McMaster research submitted to the Journal Biomaterials: "These results triggered presentations at International scientific conferences confirming that PGX-YBG is suitable for inhalation and can act through a newly discovered mechanism of action through specific binding on white blood cells (macrophages) involved in the inflammation and fibrotic process. A comprehensive scientific article was recently submitted to the Biomaterials scientific journal." news release
"Ongoing assessment as a potential drug candidate for a Phase 1 clinical trial." news release. In an October 2023 presentation Gilles anticipated only a short toxicology study was required of about 6 months. Dr. Martin Kolb said it preclinical results are replicated it could profoundly change the treatment landscape.
5) Product launch: "Ceapro’s team anticipates the official commercial launch of its approved natural health product in H2 2024, marking an important chapter in the Company's journey toward promoting wellness while expanding its business model."
6) July 18, 2024 CZO announced the launch of the next phase of research with the Angiogenesis Foundation. The prior research was called a "home run" by Gilles and used animal models other companies use to justify human clinical trials. Dr. Li used an 'Intel Inside' analogy in talking about the breadth of potential application.
7) AEZS has been conducting research with Harvard on NMOSD and was expected to have talks with regulators concerning the path forward for two programs in the near term. It has targeted its ALS and delayed parathyroid deficiency drug for potential partnering. Do we have a scientific, regulatory or parnering update on AEZS's pipeline?